FDA warns Princess Lifestyles over unapproved drug claims, CGMP failures, and ephedrine-alkaloid supplement Stomaisu.
What happened
FDA inspected Princess Lifestyles’ San Gabriel, California facility on March 3, 9, and 26, 2021, and in February 2022 reviewed its website where it takes orders. FDA found disease-treatment claims making TMAXX and PS Brain unapproved new drugs, multiple dietary supplement CGMP failures, and that Stomaisu contains Pinellia ternata, a plant with ephedrine alkaloids that FDA says presents an unreasonable risk.
What FDA found
FDA said website claims that TMAXX balances cholesterol and that PS Brain improves cognitive function in dementia or Alzheimer’s patients make these supplements unapproved new drugs.
21 U.S.C. §§ 321(g)(1)(B), 321(p), 331(d), 355(a)FDA said PS Brain is misbranded because it is intended for diseases that a layperson cannot safely self-treat, so it lacks adequate directions for use.
21 U.S.C. § 352(f)(1)The company lacked written quality control procedures and had no records that quality control reviewed and approved finished supplements for release.
21 CFR 111.103; 21 CFR 111.140(b)(2)The company did not set identity specifications for ingredients it supplied to its contract manufacturer for TMAXX and Livelyn.
21 CFR 111.70(b)(1)Stomaisu is adulterated because its label lists Pinellia ternata, a plant containing ephedrine alkaloids that FDA says presents an unreasonable risk of illness or injury.
21 U.S.C. § 342(f)(1)(A); 21 CFR 119.1Several supplement labels were misbranded, including Arthrolyn not naming the shellfish species, missing domestic adverse-event contact information, foreign-language labels not repeating all required information, wrong serving sizes, and Supplement Facts format errors.
21 U.S.C. § 343; 21 CFR 101
What FDA wants
Within 15 working days, notify FDA in writing of the specific steps taken to correct the violations, including how recurrence will be prevented and copies of related documentation. If corrections cannot be completed in that time, state the reason and the date by which they will be completed.
Who should pay attention
- retailers and online marketplaces selling these supplements
- brand owners that release contract-manufactured supplements
- quality teams managing supplement CGMP and labeling
This is a summary. Read the original letter on fda.gov.